Relevant Literature: Amyloidosis

A small sampling of the more than 420 articles on amyloidosis by Mayo authors

AL Amyloidosis

1. Sidana S, et al. Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains. Leukemia. 2017.

2.Muchtar E, et al. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood. 2017;129(15):2111-9.

3. Sher T, et al. First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis. Blood. 2016;128(15):1987-9.

4. Dispenzieri A, et al. Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement. Mayo Clin Proc. 2015;90(8):1054-81.

5. Gertz MA. Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment. Am J Hematol. 2016;91(9):947-56.

6. Grogan M, et al. Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: The Mayo Clinic experience. World J Transplant. 2016;6(2):380-8.

7. Dispenzieri A, et al. Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center. Bone Marrow Transplant. 2013;48(10):1302-7.

8. Kumar S, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(9):989-95.

9. Mikhael JR, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012;119(19):4391-4.

10. Dispenzieri A, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2004;104(6):1881-7.

11. Gertz MA, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005;79(4):319-28.

Diagnosis of amyloidosis

1. Vrana JA, et al. Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics. Haematologica. 2014;99(7):1239-47.

2. Vrana JA, et al. Classification of amyloidosis by laser microdissection and mass spectrometry based proteomic analysis in clinical biopsy specimens. Blood. 2009;114(24):4957-9.

ATTR amyloidosis

1. Swiecicki PL, et al. Hereditary ATTR amyloidosis: a single-institution experience with 266 patients. Amyloid. 2015;22(2):123-31.

2. Grogan M, et al. Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. Journal of the American College of Cardiology. 2016;68(10):1014-20.

3. Banerjee D, et al. Outcomes of Patients With Familial Transthyretin Amyloidosis After Liver Transplantation. Progress in Transplantation. 2017;27(3):246-50.

4. Muchtar E, et al. Acquired transthyretin amyloidosis after domino liver transplant: Phenotypic correlation, implication of liver retransplantation. Journal of the neurological sciences. 2017;379:192-7.

5. Cornwell GG, 3rd, et al. Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am J Med. 1983;75(4):618-23.

Other amyloidoses

1. Bois MC, et al. Apolipoprotein A-IV-Associated Cardiac Amyloidosis. Journal of the American College of Cardiology. 2017;69(17):2248-9.

2. Nasr SH,  et al. Novel Type of Renal Amyloidosis Derived from Apolipoprotein-CII. J Am Soc Nephrol. 2017;28(2):439-45.